The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative that could allow the Trump administration to impose restrictions on its use, The Wall Street Journal reports.

The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).

Each year, the global oncology community descends on Chicago for ASCO, where buzzy data drops, practice-changing posters and packed sessions offer a look at where cancer care is headed next. In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Fierce Pharma’s Zoey Becker and Angus Liu […]

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.

Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology.

Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics’ Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market since the FDA granted it accelerated approval in 2021.